Literature DB >> 31120376

The MSBase registry: Informing clinical practice.

Tomas Kalincik1, Helmut Butzkueven2.   

Abstract

Over the last decade, clinical registries have significantly contributed to the pool of evidence that supports management decisions in patients with multiple sclerosis. Being the largest international registry of multiple sclerosis and neuroimmunological disorders, MSBase collects demographic, clinical and limited paraclinical information from patients managed in different regions and under various circumstances. In this review, we will provide an overview of its published output, with focus on the information with impact on the management of multiple sclerosis.

Entities:  

Keywords:  MSBase; Observational data; registry; relapses; therapy

Mesh：

Year:  2019        PMID： 31120376     DOI： 10.1177/1352458519848965

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  10 in total

1.  NARCOMS and Other Registries in Multiple Sclerosis: Issues and Insights.

Authors:  Ruth Ann Marrie; Gary R Cutter; Robert J Fox; Timothy Vollmer; Tuula Tyry; Amber Salter
Journal:  Int J MS Care       Date:  2021-12-29

2.  Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

Authors:  M Lefort; S Sharmin; J B Andersen; M Magyari; T Kalincik; E Leray; S Vukusic; R Casey; M Debouverie; G Edan; J Ciron; A Ruet; J De Sèze; E Maillart; H Zephir; P Labauge; G Defer; C Lebrun-Frenay; T Moreau; E Berger; P Clavelou; J Pelletier; B Stankoff; O Gout; E Thouvenot; O Heinzlef; A Al-Khedr; B Bourre; O Casez; P Cabre; A Montcuquet; A Wahab; J P Camdessanché; A Maurousset; H Ben Nasr; K Hankiewicz; C Pottier; N Maubeuge; D Dimitri-Boulos; C Nifle; D A Laplaud; D Horakova; E K Havrdova; R Alroughani; G Izquierdo; S Eichau; S Ozakbas; F Patti; M Onofrj; A Lugaresi; M Terzi; P Grammond; F Grand'Maison; B Yamout; A Prat; M Girard; P Duquette; C Boz; M Trojano; P McCombe; M Slee; J Lechner-Scott; R Turkoglu; P Sola; D Ferraro; F Granella; V Shaygannejad; J Prevost; D Maimone; O Skibina; K Buzzard; A Van der Walt; R Karabudak; B Van Wijmeersch; T Csepany; D Spitaleri; S Vucic; N Koch-Henriksen; F Sellebjerg; P S Soerensen; C C Hilt Christensen; P V Rasmussen; M B Jensen; J L Frederiksen; S Bramow; H K Mathiesen; K I Schreiber; H Butzkueven
Journal:  BMC Med Res Methodol       Date:  2022-05-30       Impact factor: 4.612

3.  The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration.

Authors:  Mitchell T Wallin; Ruth Whitham; Heidi Maloni; Shan Jin; Jonathan Duckart; Jodie Haselkorn; William J Culpepper
Journal:  Fed Pract       Date:  2020-04

4.  Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.

Authors:  Wei Zhen Yeh; Putu Ayu Widyastuti; Anneke Van der Walt; Jim Stankovich; Eva Havrdova; Dana Horakova; Karolina Vodehnalova; Serkan Ozakbas; Sara Eichau; Pierre Duquette; Tomas Kalincik; Francesco Patti; Cavit Boz; Murat Terzi; Bassem I Yamout; Jeannette Lechner-Scott; Patrizia Sola; Olga G Skibina; Michael Barnett; Marco Onofrj; Maria José Sá; Pamela Ann McCombe; Pierre Grammond; Radek Ampapa; Francois Grand'Maison; Roberto Bergamaschi; Daniele L A Spitaleri; Vincent Van Pesch; Elisabetta Cartechini; Suzanne Hodgkinson; Aysun Soysal; Albert Saiz; Melissa Gresle; Tomas Uher; Davide Maimone; Recai Turkoglu; Raymond Mm Hupperts; Maria Pia Amato; Franco Granella; Celia Oreja-Guevara; Ayse Altintas; Richard A Macdonell; Tamara Castillo-Trivino; Helmut Butzkueven; Raed Alroughani; Vilija G Jokubaitis
Journal:  Neurology       Date:  2021-04-20       Impact factor: 9.910

Review 5.  Standardization and digitization of clinical data in multiple sclerosis.

Authors:  Marcus D'Souza; Athina Papadopoulou; Christophe Girardey; Ludwig Kappos
Journal:  Nat Rev Neurol       Date:  2021-01-15       Impact factor: 42.937

6.  Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Authors:  Tomas Kalincik; Ibrahima Diouf; Sifat Sharmin; Charles Malpas; Tim Spelman; Dana Horakova; Eva Kubala Havrdova; Maria Trojano; Guillermo Izquierdo; Alessandra Lugaresi; Alexandre Prat; Marc Girard; Pierre Duquette; Pierre Grammond; Vilija Jokubaitis; Anneke van der Walt; Francois Grand'Maison; Patrizia Sola; Diana Ferraro; Vahid Shaygannejad; Raed Alroughani; Raymond Hupperts; Murat Terzi; Cavit Boz; Jeannette Lechner-Scott; Eugenio Pucci; Vincent Van Pesch; Franco Granella; Roberto Bergamaschi; Daniele Spitaleri; Mark Slee; Steve Vucic; Radek Ampapa; Pamela McCombe; Cristina Ramo-Tello; Julie Prevost; Javier Olascoaga; Edgardo Cristiano; Michael Barnett; Maria Laura Saladino; Jose Luis Sanchez-Menoyo; Suzanne Hodgkinson; Csilla Rozsa; Stella Hughes; Fraser Moore; Cameron Shaw; Ernest Butler; Olga Skibina; Orla Gray; Allan Kermode; Tunde Csepany; Bhim Singhal; Neil Shuey; Imre Piroska; Bruce Taylor; Magdolna Simo; Carmen-Adella Sirbu; Attila Sas; Helmut Butzkueven
Journal:  Neurology       Date:  2020-12-28       Impact factor: 9.910

7.  Digital Dementia Registry Bavaria-digiDEM Bayern: study protocol for a multicentre, prospective, longitudinal register study.

Authors:  Nikolas Dietzel; Lara Kürten; Linda Karrer; Michael Reichold; Laura Köhler; Andreas Nagel; Christina Chmelirsch; Kathrin Seebahn; Markus Hladik; Sebastian Meuer; Anna Kirchner; Kristina Holm; Marina Selau; Marco Wendel; Jörg Trinkwalter; Hans-Ulrich Prokosch; Elmar Graessel; Peter L Kolominsky-Rabas
Journal:  BMJ Open       Date:  2021-02-08       Impact factor: 2.692

Review 8.  A Quantitative Synthesis of Eight Decades of Global Multiple Sclerosis Research Using Bibliometrics.

Authors:  Ismail Ibrahim Ismail; Mohammed Saqr
Journal:  Front Neurol       Date:  2022-02-24       Impact factor: 4.003

9.  Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

Authors:  Timothy Spelman; William L Herring; Thibaut Dort; Yuanhui Zhang; Michael Tempest; Isobel Pearson; Ulrich Freudensprung; Carlos Acosta; Robert Hyde; Eva Havrdova; Dana Horakova; Maria Trojano; Giovanna De Luca; Alessandra Lugaresi; Guillermo Izquierdo; Pierre Grammond; Pierre Duquette; Raed Alroughani; Eugenio Pucci; Franco Granella; Jeannette Lechner-Scott; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Csilla Rozsa; Cavit Boz; Raymond Hupperts; Vincent Van Pesch; Celia Oreja-Guevara; Anneke van der Walt; Vilija G Jokubaitis; Tomas Kalincik; Helmut Butzkueven
Journal:  Pharmacoeconomics       Date:  2021-12-18       Impact factor: 4.981

10.  The role of machine learning in developing non-magnetic resonance imaging based biomarkers for multiple sclerosis: a systematic review.

Authors:  Md Zakir Hossain; Elena Daskalaki; Anne Brüstle; Jane Desborough; Christian J Lueck; Hanna Suominen
Journal:  BMC Med Inform Decis Mak       Date:  2022-09-15       Impact factor: 3.298
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.